Inhibition of osteoclastogenesis by RNA interference targeting RANK

BMC Musculoskeletal Disorders

Volumn 13, Issue , 2012, Pages

  Ma, Ruofan ^a   Xu, Jie ^a   Dong, Bin ^a   Kauther, Max Daniel ^b   Jäger, Marcus ^b   Wedemeyer, Christian ^b  

^a SUN YAT SEN UNIVERSITY   (China)

^b UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

Cell culture; Inhibition; RANK; RNA interference

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; SHORT HAIRPIN RNA;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BONE MARROW CELL; CELL ASSAY; CELL DIFFERENTIATION; CONTROLLED STUDY; HUMAN; MACROPHAGE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; OSTEOCLAST; OSTEOCLASTOGENESIS; OSTEOLYSIS; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RETROVIRUS; RNA INTERFERENCE; STAINING; WESTERN BLOTTING;

ACID PHOSPHATASE; ANIMALS; BIOLOGICAL MARKERS; BLOTTING, WESTERN; CELL DIFFERENTIATION; CELLS, CULTURED; GENETIC VECTORS; ISOENZYMES; MACROPHAGES; MICE; MICE, INBRED BALB C; OSTEOCLASTS; OSTEOLYSIS; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; RETROVIRIDAE; RNA INTERFERENCE; RNA, SMALL INTERFERING; TRANSFECTION;

EID: 84865174161     PISSN: None     EISSN: 14712474     Source Type: Journal    
DOI: 10.1186/1471-2474-13-154     Document Type: Article

References (33)

1. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Suda T, Takahashi N, Udagawa N, Jimi E, Gillespie MT, Martin TJ, Endocr Rev Jun 1999 20 3 345 357 (Pubitemid 30649812)
2. Regulation of the differentiation and function of osteoclasts. Chambers TJ, J Pathol 2000 192 1 4 13 10.1002/1096-9896(2000)9999:9999<::AID- PATH645>3.0.CO;2-Q 10951393
3. The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. Hofbauer LC, Khosla S, Dunstan CR, Lacey DL, Boyle WJ, Riggs BL, J Bone Miner Res 2000 15 1 2 12 10.1359/jbmr.2000.15.1.2 10646108 (Pubitemid 30026926)
4. Commitment and differentiation of osteoclast precursor cells by the sequential expression of c-Fms and receptor activator of nuclear factor kappaB (RANK) receptors. Arai F, Miyamoto T, Ohneda O, Inada T, Sudo T, Brasel K, Miyata T, Anderson DM, Suda T, J Exp Med 1999 190 12 1741 1754 10.1084/jem.190.12.1741 10601350 (Pubitemid 30013841)
5. Osteoclast differentiation and activation. Boyle WJ, Simonet WS, Lacey DL, Nature 2003 423 6937 337 342 10.1038/nature01658 12748652 (Pubitemid 40852708)
6. All TRAFs are not created equal: common and distinct molecular mechanisms of TRAF-mediated signal transduction. Chung JY, Park YC, Ye H, Wu H, J Cell Sci 2002 115 Pt 4 679 688 11865024 (Pubitemid 34196328)
7. The TNF and TNF receptor superfamilies: integrating mammalian biology. Locksley RM, Killeen N, Lenardo MJ, Cell 2001 104 4 487 501 10.1016/S0092- 8674(01)00237-9 11239407 (Pubitemid 32201945)
8. Regulatory roles and molecular signaling of TNF family members in osteoclasts. Feng X, Gene 2005 350 1 1 13 10.1016/j.gene.2005.01.014 15777737
9. Functional identification of three receptor activator of NF-kappa B cytoplasmic motifs mediating osteoclast differentiation and function. Liu W, Xu D, Yang H, Xu H, Shi Z, Cao X, Takeshita S, Liu J, Teale M, Feng X, J Biol Chem 2004 279 52 54759 54769 10.1074/jbc.M404687200 15485878 (Pubitemid 40053221)
10. RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis. Nakagawa N, Kinosaki M, Yamaguchi K, Shima N, Yasuda H, Yano K, Morinaga T, Higashio K, Biochem Biophys Res Commun 1998 253 2 395 400 10.1006/bbrc.1998.9788 9878548 (Pubitemid 29026714)
11. RANKL maintains bone homeostasis through c-Fos-dependent induction of interferon-beta. Takayanagi H, Kim S, Matsuo K, Suzuki H, Suzuki T, Sato K, Yokochi T, Oda H, Nakamura K, Ida N, Wagner EF, Taniguchi T, Nature 2002 416 6882 744 749 10.1038/416744a 11961557 (Pubitemid 34429151)
12. Applications of RNA interference in cancer therapeutics as a powerful tool for suppressing gene expression. He S, Zhang D, Cheng F, Gong F, Guo Y, Mol Biol Rep 2009 36 2153 2163 10.1007/s11033-008-9429-7 19117119
13. Downregulation of BMI-1 enhances 5-fluorouracil-induced apoptosis in nasopharyngeal carcinoma cells. Qin L, Zhang X, Zhang L, Feng Y, Weng GX, Li MZ, Kong QL, Qian CN, Zeng YX, Zeng MS, Liao DF, Song LB, Biochem Biophys Res Commun 2008 371 3 531 535 10.1016/j.bbrc.2008.04.117 18452707
14. Generation of murine bone marrow derived macrophages in a standardised serum-free cell culture system. Eske K, Breitbach K, Köhler J, Wongprompitak P, Steinmetz I, J Immunol Methods 2009 342 1-2 13 19 19133267
15. The biology of aseptic osteolysis. Holt G, Murnaghan C, Reilly J, Meek RM, Clin Orthop Relat Res 2007 460 240 252 17620815 (Pubitemid 47056504)
16. Inhibition of RANKL blocks skeletal tumor progression and improves survival in a mouse model of breast cancer bone metastasis. Canon JR, Roudier M, Bryant R, Morony S, Stolina M, Kostenuik PJ, Dougall WC, Clin Exp Metastasis 2008 25 2 119 129 10.1007/s10585-007-9127-1 18064531
17. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Hsu H, Lacey DL, Dunstan CR, Solovyev I, Colombero A, Timms E, Tan HL, Elliott G, Kelley MJ, Sarosi I, Wang L, Xia XZ, Elliott R, Chiu L, Black T, Scully S, Capparelli C, Morony S, Shimamoto G, Bass MB, Boyle WJ, Proc Natl Acad Sci U S A 1999 96 7 3540 3545 10.1073/pnas.96.7.3540 10097072 (Pubitemid 29168945)
18. Osteoprotegerin is a soluble decoy receptor or tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells. Shipman CM, Croucher PI, Cancer Res 2003 63 5 912 916 12615702 (Pubitemid 36278418)
19. RANKL inhibition by osteoprotegerin prevents bone loss without affecting local or systemic inflammation parameters in two rat arthritis models: comparison with anti-TNFalpha or anti-IL-1 therapies. Stolina M, Schett G, Dwyer D, Vonderfecht S, Middleton S, Duryea D, Pacheco E, Van G, Bolon B, Feige U, Zack D, Kostenuik P, Arthritis Res Ther 2009 11 6 187 10.1186/ar2879 20003323
20. Fully human therapeutic monoclonal antibodies. Weiner LM, J Immunotherapy 2006 29 1 1 9 10.1097/01.cji.0000192105.24583.83
21. RANKL-RANK signaling in osteoclastogenesis and bone disease. Wada T, Nakashima T, Hiroshi N, Penninger JM, Trends Mol Med 2006 2 1 17 25 (Pubitemid 43089652)
22. Characterization of the intracellular domain of receptor activator of NF-kappaB (RANK). Interaction with tumor necrosis factor receptor-associated factors and activation of NF-kappab and c-Jun N-terminal kinase. Darnay BG, Haridas V, Ni J, Moore PA, Aggarwal BB, J Biol Chem 1998 273 32 20551 20555 10.1074/jbc.273.32.20551 9685412 (Pubitemid 28377625)
23. Glutaredoxin2 isoform b (Glrx2b) promotes RANKL-induced osteoclastogenesis through activation of the p38-MAPK signaling pathway. Yeon JT, Choi SW, Park KI, Choi MK, Kim JJ, Youn BS, Lee MS, Oh J, BMB Rep 2012 45 3 171 176 10.5483/BMBRep.2012.45.3.171 22449704
24. Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice. Soriano P, Montgomery C, Geske R, Bradley A, Cell 1991 64 4 693 702 10.1016/0092-8674(91)90499-O 1997203 (Pubitemid 121001157)
25. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. Emery JG, McDonnell P, Burke MB, Deen KC, Lyn S, Silverman C, Dul E, Appelbaum ER, Eichman C, DiPrinzio R, Dodds RA, James IE, Rosenberg M, Lee JC, Young PR, J Biol Chem 1998 273 23 14363 14367 10.1074/jbc.273.23.14363 9603945 (Pubitemid 28319153)
26. Critical roles of c-Jun signaling in regulation of NFAT family and RANKL-regulated osteoclast differentiation. Ikeda F, Nishimura R, Matsubara T, Tanaka S, Inoue J, Reddy SV, Hata K, Yamashita K, Hiraga T, Watanabe T, Kukita T, Yoshioka K, Rao A, Yoneda T, J Clin Invest 2004 114 4 475 484 15314684 (Pubitemid 39572097)
27. The phosphatidylinositol 3-kinase, p38, and extracellular signal-regulated kinase pathways are involved in osteoclast differentiation. Lee SE, Woo KM, Kim SY, Kim HM, Kwack K, Lee ZH, Kim HH, Bone 2002 30 1 71 77 10.1016/S8756-3282(01)00657-3 11792567 (Pubitemid 34044303)
28. Involvement of p38 mitogen-activated protein kinase signaling pathway in osteoclastogenesis mediated by receptor activator of NF-kappa B ligand (RANKL). Matsumoto M, Sudo T, Saito T, Osada H, Tsujimoto M, J Biol Chem 2000 275 40 31155 31161 10859303
29. T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-gamma. Takayanagi H, Ogasawara K, Hida S, Chiba T, Murata S, Sato K, Takaoka A, Yokochi T, Oda H, Tanaka K, Nakamura K, Taniguchi T, Nature 2000 408 6812 600 605 10.1038/35046102 11117749
30. Suppressed severity of collagen-induced arthritis by in vivo transfection of nuclear factor kappaB decoy oligodeoxynucleotides as a gene therapy. Tomita T, Takeuchi E, Tomita N, Morishita R, Kaneko M, Yamamoto K, Nakase T, Seki H, Kato K, Kaneda Y, Ochi T, Arthritis Rheum 1999 42 12 2532 2542 10.1002/1529-0131(199912)42:12<2532::AID-ANR5>3.0.CO;2-2 10615998 (Pubitemid 30327169)
31. Role of RANKL in physiological and pathological bone resorption and therapeutics targeting the RANKL-RANK signaling system. Tanaka S, Nakamura K, Takahasi N, Suda T, Immunol Rev 2005 208 30 49 10.1111/j.0105-2896.2005.00327.x 16313339 (Pubitemid 41746383)
32. Approaches for chemically synthesized siRNA and vector-mediated RNAi. Amarzguioui M, Rossi JJ, Kim D, FEBS Lett 2005 579 26 5974 5981 10.1016/j.febslet.2005.08.070 16199038 (Pubitemid 41484142)
33. Delivery of RNA interference. Li CX, Parker A, Menocal E, Xiang S, Borodyansky L, Fruehauf JH, Cell Cycle 2006 5 18 2103 2109 10.4161/cc.5.18.3192 16940756 (Pubitemid 44553744)